The safety and efficacy of granisetron (10 μg/kg and 40 μg/kg) were evaluated during a second (n = 393) and third (n = 200) cycle of chemotherapy in this multicenter, double-blind, randomized, parallel-group study. Granisetron was administered as a single intravenous dose before the start of cisplatin chemotherapy (≤60 mg/m2). Total control (no vomiting, no retching, no nausea, and no use of antiemetic rescue medications) after the first 24 hr following chemotherapy was achieved in 40% and 49% of patients in cycles 2 and 3, respectively, for the 10 μg/kg group, and in 42% and 38% of patients in Cycles 2 and 3, respectively, for the 40μg/kg group. Both dose levels of granisetron were well tolerated. The results demonstrate comparable efficacy between the 10 μg/kg and 40 μg/kg doses of granisetron in preventing cause and vomiting during repeat cycles of high-dose cisplatin- based chemotherapy. The results of this study show that granisetron 10 μg/kg is safe and well tolerated, and remains effective with repeat cycle use.
ASJC Scopus subject areas
- Cancer Research